OPDP Bulletins

  • OPA Bulletin - May 28, 2019

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA and Neighbourhood Pharmacies oppose government's proposal to extract $140 million annually from pharmacy
    • Last chance to register for conference - registration closes Thursday!
    • Discontinuation Notice - PrDepo-Provera® (medroxyprogesterone acetate, USP) 50 mg/mL in 1 x 5 mL Vial
    • Drug Supply Health System Alert: OncoTICE
    • IMPORTANT: Notification Regarding PrNORVASC® (amlodipine besylate) 10 mg tablets in bottles of 250.
    • Re-issuing Spring Issue of Ontario Pharmacist

    • Billing 101: Ontario Drug Benefit (ODB) and Third-Party Insurance
    • How-To: Ontario’s Pharmaceutical Opinion Program
    • Asthma Management: The Essentials

    • Summer's almost here! Time to get your Canada's Wonderland passes
    • Ask the Practice Support Network

    • Are you considering Joining a Local Area Network (LAN) or Wide Area Network (WAN)?

    • DDD Notice No. 19081 posted May 23, 2019 ODB FORMULARY – EDITION NO. 43, Summary of Changes – May 2019

  • OPA Bulletin - March 26, 2019

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    • OPA Process Map and Pharmacy Tool for OHIP+
    • ICYMI: Empowering Canadian Pharmacy Practice
    • Pharmacy Experience Pharmacie 2019 is open for registration!
    • Research Study: The Ontario Digital Service and Ministry of Health and Long-Term Care
    • Canadian Federation of Pharmacy Campaign Drive 1 Million for 25
    • OPA Supports Broader Discussion on Impact of Removal of Private Label Ban

    • Implementing Smoking Cessation Services in the Pharmacy
    • Asthma Management: The Essentials
    • MedsCheck Refresh: Implementing the Revitalized Program

    • Last Call for OPA Awards
    • Ask the Customer Experience and Administration Team

    • OPA Secure Health Plan Q&A
    • It's Movie Ticket Time with COSECO!

    • DDD Notice No. 19057 posted March 20, 2019 Prescription Forgery Alert
    • DDD Notice No. 19058 posted March 21, 2019 ODB FORMULARY – EDITION NO. 43, Summary of Changes – March 2019
    • DDD Notice No. 19059 posted March 25, 2019 Claim Submission/Reversal and Special Authorization (Allergen) forms

    • Extraneal peritoneal dialysis solution - Advisory
    • Important Safety Information on DARZALEX (daratumumab) and Hepatitis B Virus Reactivation - Janssen Inc.

  • OPA Bulletin - November 20, 2018

    This content is only available to Association members. Please log in to access this content.

    Become a member

    or Sign In

    Pharmacy News
    • OPDP Notice No. 18145 posted November 16, 2018 Notice from the Executive Officer

    News from OPA
    • Membership and DIRC subscription campaigns open! Take advantage of early bird
    • Research and Advocacy
    • CPhA/OPA Conference - Pharmacy Experience Pharmacie (PxP) Call for Speakers
    • Ask the Customer Experience and Administration Team
    • Highlights in Professional Development​
    • OPA's PLI Insurance - Best-in-Class!

  • OPDP Notice No. 17109

    OPDP Notice No. 17109 posted September 21, 2017 ODB FORMULARY – EDITION NO. 42, Summary of Changes – September 2017 We are pleased to provide you with the Summary of Changes – September 2017 to Edition No. 42 of the Ontario Drug Benefit (ODB) …

    September 03, 2013
  • OPDP Notice No. 17108

    OPDP Notice No. 17108 posted September 21, 2017 Notice from the Executive Officer: Changes to Fentanyl Dispensing Ontario Public Drug Programs is committed to supporting the appropriate prescribing and dispensing of opioids and addressing the …

    September 03, 2013
  • OPDP BULLETINS August 23-29, 2017

    OPDP Notice No. 17100 posted August 23, 2017 ODB FORMULARY – EDITION NO. 42, Summary of Changes – August 2017 OPDP Notice No. 17101 posted August 23, 2017 Notice from the Executive Officer: Thyroid (Dessicated Thyroid) Delisting OPDP Notice …

    September 03, 2013
  • OPDP BULLETINS August 2 - 9, 2017

    OPDP Notice. 17096 posted August 3, 2017 Prescription Forgery Alert OPDP Notice No. 17097 posted August 3, 2017 Notice from the Executive Officer: Reimbursement and Claim Submissions for Mifepristone/Misoprostol (Mifegymiso) OPDP Notice No. 1 …

    September 03, 2013
  • OPDP BULLETINS July 26 - August 1, 2017

    OPDP Notice. 17092A posted July 28, 2017 Addendum to ODB Formulary – Edition 42, Summary of Changes – July 2017 OPDP Notice No.17095 posted August 1, 2017 Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit …

    September 03, 2013
  • OPDP BULLETINS July 18-25, 2017

    OPDP Notice. 17091 posted July 20, 2017 E-FORMULARY OUTAGE NOTIFICATION TO ODP AGENCIES OPDP Notice. 17092 posted July 21, 2017 ODB FORMULARY – EDITION NO. 42, Summary of Changes – July 2017 OPDP Notice No. 17093 posted July 21, 2017 Notice …

    September 03, 2013
  • OPDP BULLETINS July 5-11, 2017

    OPDP Notice. 17082 posted July 5, 2017 CPSO Notices June 2017 - Release 1 of 2 OPDP Notice. 17083 posted July 5, 2017 CPSO Notices June 2017 - Release 2 of 2 OPDP Notice. 17084 posted July 7, 2017 E-FORMULARY OUTAGE NOTIFICATION TO ODP …

    September 03, 2013
Back to top